Pulmonary Therapy (Aug 2020)

Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

Alice Tsai,
Shu-Pei Wu,
Eric Haseltine,
Sanjeev Kumar,
Samuel M. Moskowitz,
Paul Panorchan,
Kushal Shah

Affiliations

Alice Tsai: Vertex Pharmaceuticals Incorporated
Shu-Pei Wu: Vertex Pharmaceuticals Incorporated
Eric Haseltine: Vertex Pharmaceuticals Incorporated
Sanjeev Kumar: Vertex Pharmaceuticals Incorporated
Samuel M. Moskowitz: Vertex Pharmaceuticals Incorporated
Paul Panorchan: Vertex Pharmaceuticals Incorporated
Kushal Shah: Vertex Pharmaceuticals Incorporated

DOI: https://doi.org/10.1007/s41030-020-00128-3
Journal volume & issue: Vol. 6, no. 2
pp. 287 – 287

Abstract

The original version of this article unfortunately contained a mistake.

Published in Pulmonary Therapy

ISSN: 2364-1754 (Print); 2364-1746 (Online)
Publisher: Adis, Springer Healthcare
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://www.springer.com/journal/41030

About the journal